Idera Pharmaceuticals, Inc. (IDRA) Announces Initiation of Lupus Clinical Development Program With Phase 1 Trial of IMO-8400
11/13/2012 9:28:26 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced the initiation of dosing in a Phase 1 trial of IMO-8400. IMO-8400 is an antagonist of Toll-like receptors (TLRs) 7, 8 and 9, and is the second clinical candidate in Idera’s autoimmune disease program. Idera expects to develop IMO-8400 for the treatment of lupus as an initial indication. Idera also announced the presentation of preclinical data on IMO-8400 at the American College of Rheumatology that support its potential to treat autoimmune diseases through inhibition of Th1, Th17, and inflammasome activation.